Cellect Biotechnology Ltd, formerly Cellect Biomed Ltd, is an Israel-based company engaged in regenerative medicine through the development of products facilitating immune stem cell selection. The Company’s platform technology is based on the game changing perception that the functional properties of stem cells rather than appearance should be used for their identification, selection and utilization. The Company’s first product is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents. While these molecules induce apoptosis (programmed cell death) in mature cells, they spare stem cells. This differential sensitivity is used to improve the outcome of bone marrow transplantation mainly by eliminating severe adverse effects.
Up over 20% pre-market on positive trial results Cellect Announces Positive Clinical Trial Results Source: http://www.econotimes.com/Cellect-Announces-Positive-Clinical-Trial-Results-549744
Up 23% pre-market Cellect Announces Successful First Cancer Patient Stem Cell Transplant Source: https://globenewswire.com/news-rele...irst-Cancer-Patient-Stem-Cell-Transplant.html
TEL AVIV, Israel, March 27, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (APOP) (APOP), a developer of stem cell selection technology, announced today that the first stem cell transplant procedure has been successfully performed using its ApoGraft™ technology in the Company’s Phase I/II clinical trial in a blood cancer patient. Up to 50 percent of stem cell transplant procedures, such as bone marrow transplants, result in life-threatening rejection disease, known as Graft-versus-Host-Disease (GvHD). Cellect’s ApoGraft™ technology is aiming to turn stem cell transplants into a simple, safe and cost effective process, reducing the associated severe side effects, such as rejection and many other risks. Dr. Shai Yarkoni, Cellect’s CEO said, “After 15 years of research, this is the first time we have used our technology on a cancer patient suffering from life-threatening conditions. It is a first good step on a road that we hope will lead to stem cell based regenerative medicine becoming a safe commodity treatment at every hospital in the world
